Just months after its acquisition by private equity fund Astorg, the French specialist in biotech active ingredients and diagnostic kits for the beauty, pharmaceutical, nutraceutical and biotechnology sectors has carried out three consecutive acquisitions.

Following last month’s acquisition of Mibelle Biochemistry, a Swiss specialist in high-performance cosmetic active ingredients, Solabia has announced two new deals: the purchase of Seqens’ botanical active ingredients and in vitro diagnostics business, and the acquisition of Xebios Diagnostics Group, a microbiological diagnostics solution provider with operations in Germany and the Netherlands.

High performance botanical active ingredients

Focused on the development and manufacturing of high-performance plant-based active ingredients for cosmetics, as well as plasmas and serums for diagnostic applications, Seqens’ Botanical Actives and In Vitro Diagnostics (IVD) business operates from a site in Limoges, France (formerly ID bio Novacap), known for its advanced botanical extraction and high-end manufacturing capabilities. Its ingredients and diagnostic solutions are marketed worldwide and used by leading brands across the cosmetics and pharmaceutical industries.

Through this operation, Solabia reinforces its global position as a leading supplier of high performance substantiated botanical active ingredients for cosmetics applications, while also securing a critical raw material supply for its diagnostics activities.

Microbiological testing

For its part, the acquisition of Xebios Diagnostics Group, which has built a strong reputation in diagnostic culture media and reagents for the analysis of drinking water, food and beverages, cosmetics and clinical samples, enables Solabia to significantly reinforce and expand its European diagnostics footprint and activities, while strengthening its manufacturing base across France, Germany, and the Netherlands.

“This acquisition marks a significant step in our ambition to build a leading European diagnostics platform," said Jean-Baptiste Dellon, CEO of Solabia.

After acquiring PolymerExpert in 2024, these three new acquisitions are set to push Solabia’s revenue close to EUR 250 million.